Olstein Capital Management, L.P. 13F holdings and portfolio analysis

Directly following the baseline exposes an investor to a broadly diversified but still fully equity-risk portfolio with filing-lag implementation drag. In the artifact, top5 concentration is only 10.3%, top10 is 19.13%, and top20 is 34.68%, so single-stock concentration is limited. But the same baseline still produced beta 0.86, maxDrawdown -36.05%, 3,222 trades, and 1.649 totalEstimatedCost. The main exposure is therefore not name concentration; it is market downside plus lagged 13F replication costs without positive alpha.

The clearest recent evidence is that the baseline had a few positive periods but many modestly negative excess-return windows. In periodPerformance, 2023-12-31 delivered optimizedReturn 5.77% versus benchmarkReturn 4.96% for +0.81% excess, and 2025-09-30 delivered 4.17% versus 1.49% for +2.68% excess. But several periods still lagged: 2022-12-31 was -7.01% versus -0.25% (-6.76% excess), 2023-06-30 was -7.61% versus -1.77% (-5.84%), 2024-03-31 was -0.81% versus 2.31% (-3.12%), and 2025-06-30 was 0.25% versus 4.2% (-3.95%). That pattern explains the trade-off: diversification helped survival, but the lagged baseline often missed benchmark upside and still absorbed meaningful downside.

The next thing to inspect is whether the user is comfortable with underperformance persistence after lag and turnover. Baseline weaknesses cite negative alpha and information ratio, while riskNotes highlight delayed 13F-style filing implementation and meaningful turnover. The turnoverSeries also shows several recent quarters in the low-to-high teens, including 16.44 at 2024-09-30, 15.78 at 2024-12-31, 14.15 at 2025-03-31, and 18.44 at 2025-09-30. Before accepting the baseline, a user should verify whether those lagged trades and recurring excess-return shortfalls are acceptable for their use case.